March 16, 2021 -- StrideBio has raised $81.5 million in funding to advance into the clinic its structure-guided adeno-associated virus (AAV) capsid engineering platform and pipeline of novel gene therapy candidates.
Specifically, the company will focus on four new programs targeting disorders of the monogenic central nervous system and cardiovascular system. The programs will leverage StrideBio's proprietary AAV capsids, which feature reduced seroprevalence, neuronal and cardiovascular tropism, liver de-targeting, and enhanced gene transfer efficiency compared to first-generation AAV.
Moreover, StrideBio will continue to build on its Strive platform (AAV vector engineering) with the goal of improving safety and reducing doses required for effective gene therapies.
The new funds will also be used to support continued operational growth and manufacturing capacity expansion, building on the company's current infrastructure which includes a 6,000-sq-ft good manufacturing practice (GMP) clean suite in Research Triangle Park, NC.
The series B financing was co-led by Northpond Ventures and Novo Holdings.
Copyright © 2021 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
